A case has recently been reported in which a patient undergoing hair removal treatment using an intense pulsed light (IPL) device sustained a second-degree skin burn. To read our thoughts on this click HERE.
A new Core of Knowledge syllabus has been developed and approved by British Medical Laser Association, Institute of Physics and Engineering in Medicine, and Society for Radiological Protection.
This is an area where there are rapid technical advances and there is also a wide diversity of laser users. The updated syllabus reflects the changing needs of laser and IPL user. A new Laser and IPL Safety Awareness syllabus has also been produced. This is an innovation that recognises the value of providing awareness training to staff who are not directly operating the laser. This does not seek to deliver knowledge to the depth that is required in a full Core of Knowledge course.* Core of Knowledge Syllabus 2014
* Laser and IPL Safety Awareness Syllabus
For information regarding BMLA approval of laser courses please click HERE.
The BMLA was invited by the NHS Clinical Reference Group for transgender services to comment on the requirements for suitable laser depilation services. Our response to the questions raised can be downloaded below.BMLA response to Laser Depilation Services
DATE: June 2013
REF: Laser Europe 2013
Conference date: 15th – 17th May 2013
Conference Location: The Lowry, Salford
Last month, the British Medical Laser Association (BMLA) hosted Laser Europe 2013 in Salford Quays, Manchester (UK). The conference was declared a resounding success with record delegate attendance and a fantastic scientific programme. Prof. Harry Moseley (President of the BMLA) said “The conference provided a great learning & networking opportunity for all involved. The venue was stunning and this year there was a real “buzz” of excitement and enjoyment throughout the event”
The two and a half day conference included laser training courses presented by industry experts and which covered topics from Hair removal to Fractional resurfacing. The scientific programme was equally impressive with a wide variety of invited and free papers presenting research in dermatology, PDT, Biophotonics and much more. The delegates were particularly delighted with the Vasant Oswal Oration presentation by Dr. Christine Diereckx (Belgium) on Laser Dermatology – past, present and future). Other world class guest speakers included Dr. Mario Trelles (Spain), Prof. Carsten Phillips (Germany), Prof. Serge Mordon (France), Dr Martin Kassir (USA).
The annual conference dinner was a complete sell-out as delegates were invited to the famous football ground of Manchester United (old Trafford). Those attending the dinner were given exclusive access to the terraces and ample opportunity to take pictures of the iconic stadium. During the Champagne reception and following the dinner, guests were entertained with a stunning performance by conjuring and close-up magic.
Throughout the conference those attending benefited from meeting industry experts and networking with like-minded scientists and clinicians. Feedback indicated the event was a huge success with delegates commenting “Best BMLA meeting I have been to – congratulations!” and “Excellent and well organized conference”. The BMLA committee wish to extend their thanks to all those involved with organising and supporting the event, particularly the support received from the European Laser Association, commercial sponsors and of course the many enthusiastic delegates.
Photodynamic therapy (PDT) is a treatment option for some types of cancer that involves administration of a drug that is activated by light, usually from a laser. This causes cell death. The underlying scientific principles and numerous clinical studies have been published in peer-reviewed literature1 2 3. PDT can be curative. For example, in non-melanoma skin cancers, PDT has less morbidity than cryotherapy and avoids the need for skin grafts in surgical excision of large lesions. Often it is palliative where it can bring welcome symptomatic relief and precious extra months’ quality life to the patient.
PDT has several key attractions: there is minimal loss of normal tissue; PDT can be repeated in the same area as often as required; it can be used after conventional treatments have failed or as a stand-alone treatment in appropriate patients.
There are clinics providing what is sometimes called Next Generation PDT (NGPDT) or sonodynamic therapy (SDT). In general, the treatments provided do not have the necessary scientific rigour that is expected. Often the light is delivered externally and it is claimed that this reaches the tumour but light penetration to internal cancers is insufficient for effective PDT. A critical appraisal of a clinical application of SDT has been published4. This concludes that there is no convincing data that shows that treatment carried out as reported is effective in the treatment of primary tumour and multiple metastases. Without critical safety and efficacy information, it is unjustifiable to test unproven unconventional techniques and substances in patients, particularly those in terminal stages. PDT can be used effectively in the treatment and care of appropriate cancer patients The use of so-called NGPDT or SDT cannot be recommended.
Prof Harry Moseley, Hon President British Medical Laser Association; Prof Sam Eljamel, Clinical Director Scottish PDT Centre; Prof Keyvan Moghissi, Clinical Director Yorkshire Laser Centre.References
1. Moghissi K, Dixon K, Stringer M et al. Photofrin PDT for early stage oesophageal cancer: Long term results in 40 patients and literature review. Photodiagnosis and Photodynamic Therapy 2009; 6: 159-66.
2. Allison RR, Sibata C, Gay H. PDT for cancers of the head and neck. Photodiagnosis and Photodynamic Therapy 2009; 6: 1-2.
3. Morton CA, McKenna KE, Rhodes LE et al. Guidelines for topical photodynamic therapy: update. British Journal of Dermatology 2008; 159: 1245-66.
4. Huang Z, Moseley H, Bown S. Rationale of Combined PDT and SDT Modalities for Treating Cancer Patients in Terminal Stage: The Proper Use of Photosensitizer. Integrative Cancer Therapies 2010; 9: 317-9.